Literature DB >> 24732774

Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression.

Judith Dalmau1, Margalida Rotger, Itziar Erkizia, Andri Rauch, Pedro Reche, Maria Pino, Anna Esteve, Eduard Palou, Christian Brander, Roger Paredes, Pham Phung, Bonaventura Clotet, Amalio Telenti, Javier Martinez-Picado, Julia G Prado.   

Abstract

OBJECTIVE: The study of HIV-1 rapid progressors has been limited to specific case reports. Nevertheless, identification and characterization of the viral and host factors involved in rapid progression are crucial when attempting to uncover the correlates of rapid disease outcome.
DESIGN: We carried out comparative functional analyses in rapid progressors (n = 46) and standard progressors (n = 46) early after HIV-1 seroconversion (≤1 year). The viral traits tested were viral replicative capacity, co-receptor usage, and genomic variation. Host CD8(+) T-cell responses, humoral activity, and HLA immunogenetic markers were also determined.
RESULTS: Our data demonstrate an unusual convergence of highly pathogenic HIV-1 strains in rapid progressors. Compared with standard progressors, rapid progressor viral strains show higher in-vitro replicative capacity (81.5 vs. 67.9%; P = 0.025) and greater X4/DM co-receptor usage (26.3 vs. 2.8%; P = 0.006) in early infection. Limited or absent functional HIV-1 CD8(+) T-cell responses and neutralizing activity were measured in rapid progressors. Moreover, the increase in common HLA allele-restricted CD8(+) T-cell escape mutations in rapid progressors acts as a signature of uncontrolled HIV-1 replication and early impairment of adaptive cellular responses.
CONCLUSION: Our data support a dominant role for viral factors in rapid progressors. Robust HIV-1 replication and intrinsic viral properties limit host adaptive immune responses, thus driving rapid disease progression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24732774     DOI: 10.1097/QAD.0000000000000293

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  15 in total

Review 1.  Clinical and evolutionary consequences of HIV adaptation to HLA: implications for vaccine and cure.

Authors:  Santiago Avila-Rios; Jonathan M Carlson; Mina John; Simon Mallal; Zabrina L Brumme
Journal:  Curr Opin HIV AIDS       Date:  2019-05       Impact factor: 4.283

2.  Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia.

Authors:  Diego Sánchez-Martínez; Matteo L Baroni; Francisco Gutierrez-Agüera; Heleia Roca-Ho; Oscar Blanch-Lombarte; Sara González-García; Montserrat Torrebadell; Jordi Junca; Manuel Ramírez-Orellana; Talía Velasco-Hernández; Clara Bueno; José Luís Fuster; Julia G Prado; Julien Calvo; Benjamin Uzan; Jan Cools; Mireia Camos; Françoise Pflumio; María Luisa Toribio; Pablo Menéndez
Journal:  Blood       Date:  2019-02-22       Impact factor: 22.113

3.  Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection.

Authors:  María Pernas; Laura Tarancón-Diez; Cecilio Lopez-Galindez; Ezequiel Ruiz-Mateos; Esther Rodríguez-Gallego; Josep Gómez; Julia G Prado; Concepción Casado; Beatriz Dominguez-Molina; Isabel Olivares; Maite Coiras; Agathe León; Carmen Rodriguez; Jose Miguel Benito; Norma Rallón; Montserrat Plana; Onofre Martinez-Madrid; Marta Dapena; Jose Antonio Iribarren; Jorge Del Romero; Felipe García; José Alcamí; MaÁngeles Muñoz-Fernández; Francisco Vidal; Manuel Leal
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

4.  Balance between transmitted HLA preadapted and nonassociated polymorphisms is a major determinant of HIV-1 disease progression.

Authors:  Daniela C Mónaco; Dario A Dilernia; Andrew Fiore-Gartland; Tianwei Yu; Jessica L Prince; Kristine K Dennis; Kai Qin; Malinda Schaefer; Daniel T Claiborne; William Kilembe; Jianming Tang; Matt A Price; Paul Farmer; Jill Gilmour; Anju Bansal; Susan Allen; Paul Goepfert; Eric Hunter
Journal:  J Exp Med       Date:  2016-08-22       Impact factor: 14.307

5.  Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or Death.

Authors:  Maria Casadellà; Alessandro Cozzi-Lepri; Andrew Phillips; Marc Noguera-Julian; Markus Bickel; Dalibor Sedlacek; Kai Zilmer; Bonaventura Clotet; Jens D Lundgren; Roger Paredes
Journal:  PLoS One       Date:  2017-01-27       Impact factor: 3.240

Review 6.  Host and Viral Factors in HIV-Mediated Bystander Apoptosis.

Authors:  Himanshu Garg; Anjali Joshi
Journal:  Viruses       Date:  2017-08-22       Impact factor: 5.048

7.  Identification of Interleukin-27 (IL-27)/IL-27 Receptor Subunit Alpha as a Critical Immune Axis for In Vivo HIV Control.

Authors:  M Ruiz-Riol; D Berdnik; A Llano; B Mothe; C Gálvez; S Pérez-Álvarez; B Oriol-Tordera; A Olvera; S Silva-Arrieta; M Meulbroek; F Pujol; J Coll; J Martinez-Picado; C Ganoza; J Sanchez; G Gómez; T Wyss-Coray; C Brander
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

8.  Low CD1c + myeloid dendritic cell counts correlated with a high risk of rapid disease progression during early HIV-1 infection.

Authors:  Yingying Diao; Wenqing Geng; Xuejie Fan; Hualu Cui; Hong Sun; Yongjun Jiang; Yanan Wang; Amy Sun; Hong Shang
Journal:  BMC Infect Dis       Date:  2015-08-19       Impact factor: 3.090

9.  Nonhuman TRIM5 Variants Enhance Recognition of HIV-1-Infected Cells by CD8+ T Cells.

Authors:  Esther Jimenez-Moyano; Alba Ruiz; Henrik N Kløverpris; Maria T Rodriguez-Plata; Ruth Peña; Caroline Blondeau; David L Selwood; Nuria Izquierdo-Useros; Arnaud Moris; Bonaventura Clotet; Philip Goulder; Greg J Towers; Julia G Prado
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

10.  Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?

Authors:  Inma Jarrin; Nikos Pantazis; Judith Dalmau; Andrew N Phillips; Ashley Olson; Cristina Mussini; Faroudy Boufassa; Dominique Costagliola; Kholoud Porter; Juliá Blanco; Julia Del Amo; Javier Martinez-Picado
Journal:  AIDS       Date:  2015-11       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.